Caroline Mansy
Family · Salisbury, MDNPI 1467457622
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $84,243 of the $106,366 with a category attached, or 79.2%. 25 manufacturers reported payments, led by Novo Nordisk at 44.5% of the total. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 583 payments — averaging $182.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$47K
- Lilly USA, LLC$46K
- Sanofi-aventis U.S. LLC$8K
- AstraZeneca$2K
- Bayer$1K
- Dexcom, Inc.$705
- plus $2K from 19 others
What the payments were for
- Consulting fees$5781%
- Speaking & faculty fees$84,24379%
- Travel & lodging$10,22610%
- Food & beverage$11,32011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 132 | $47,286 |
| Lilly USA, LLC | 187 | $45,634 |
| Sanofi-aventis U.S. LLC | 63 | $7,891 |
| AstraZeneca | 36 | $1,972 |
| Bayer | 43 | $1,012 |
| Dexcom, Inc. | 33 | $705 |
| Insulet Corporation | 25 | $474 |
| Abbott | 13 | $248 |
| Merck | 11 | $184 |
| Corcept Therapeutics | 7 | $169 |
| Cequr Corporation | 2 | $164 |
| Xeris Pharmaceuticals, Inc. | 7 | $142 |
| Lifescan, Inc. | 6 | $111 |
| Averitas Pharma Inc. | 3 | $61 |
| Amarin Pharma, Inc. | 3 | $56 |
| Novartis | 2 | $45 |
| Medtronic | 2 | $43 |
| Nevro Corp. | 1 | $36 |
| Tandem Diabetes Care, Inc. | 1 | $23 |
| AbbVie | 1 | $22 |
| Amgen | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Zealand Pharma US, Inc. | 1 | $18 |
| BETA Bionics, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$40,249
- RYBELSUS$30,915
- Ozempic$12,400
- SOLIQUA 100/33$4,331
- TOUJEO$2,140
- FARXIGA$1,400
- Kerendia$226
- ZEPBOUND$125
- CeQur Simplicity$101
How this compares
$106,366 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 976 | $1,534,679 |
| MounjaroTirzepatide | 717 | $1,215,295 |
| FarxigaDapagliflozin Propanediol | 354 | $401,774 |
| JardianceEmpagliflozin | 328 | $381,901 |
| TrulicityDulaglutide | 252 | $361,607 |
| Tresiba Flextouch U-200Insulin Degludec | 323 | $308,233 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 170 | $284,197 |
| Humalog Kwikpen U-200Insulin Lispro | 104 | $239,278 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 255 | $218,369 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 95 | $118,415 |
| JanuviaSitagliptin Phosphate | 65 | $91,896 |
| KerendiaFinerenone | 70 | $91,769 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 69 | $61,576 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 38 | $59,329 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 112 | $53,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $47,286 | $1,602,1401,033 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $45,634 | $1,595,7111,009 claims |
| AstraZenecaFarxiga | $1,972 | $401,774354 claims |
| Boehringer IngelheimJardiance, Tradjenta | $13 | $399,371350 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $7,891 | $118,41595 claims |
| MerckJanuvia, Janumet | $184 | $106,42383 claims |
| BayerKerendia | $1,012 | $91,76970 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.
Other family in Salisbury
- Joy MaulikSalisbury$47K
- Sarah ProffitSalisbury$10K
- Donna GraySalisbury$10K
- Erika HoffmanPotomac$226K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Ariana ChaoLutherville$85K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Kristin AttiogbeChevy Chase$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.